When was Caris Life Sciences founded?

Caris Life Sciences was founded in 1996 and raised its 1st funding round 21 years after it was founded.

Where is Caris Life Sciences located?

Caris Life Sciences is headquartered in Irving, United States. It is registered at Irving, Texas.

How many employees does Caris Life Sciences have?

As of Sep 30, 2026, the latest employee count at Caris Life Sciences is 61.

Is Caris Life Sciences a funded company?

Caris Life Sciences is a funded company, having raised a total of $1.23B across 9 funding rounds to date. The company's 1st funding round was a $248K Grant (prize money) round, raised on Jan 09, 2017.

When was the latest funding round of Caris Life Sciences?

Caris Life Sciences' latest funding was a $168M Series D round on Apr 07, 2025, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.7B in funding in 2026 to date.

What is the annual revenue of Caris Life Sciences?

Annual revenue of Caris Life Sciences is between $500M and $1B as on Dec 31, 2025

Is Caris Life Sciences a Genomics company?

The primary sectors of Caris Life Sciences are Genomics, Oncology and Clinical Genomics.

Where does Caris Life Sciences rank among its competitors?

Caris Life Sciences ranks 7th amongst 762 active competitors, of which 227 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of Caris Life Sciences?

Caris Life Sciences' top competitors include Guardant Health, Natera and BillionToOne. Among them, Guardant Health secured the most recent funding round in November, 2025.

Caris Life Sciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Sectors and market segments that Caris Life Sciences operate in

Caris Life Sciences serves in the Life Sciences market segments.The primary business model of Caris Life Sciences are:

Company Details

Developer of panomic disease profiling technologies for cancer precision medicine. The company leverages artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN for advancing the oncology precision medicine platform. It offers tumor profiling services, a complete molecular blueprint, and guiding personalized cancer treatment.

Website: www.carislifesciences.com/
Social
Registered Address: Irving, Texas

Key Metrics

Founded Year

1996

Location

Irving, United States

Stage

Public

Total Funding

$1.23B in 9 rounds

Latest Funding Round

Series D, Apr 07, 2025, $168M

Investors

Coatue & 20 more

Ranked

7^th among 762 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

61 as on Sep 30, 2026

Investment & Acquisitions

Pharmatech

Similar Companies

Guardant Health & 1022 more

Exit Details

Public

View Caris Life Sciences' full profile

Caris Life Sciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
CARIS LIFE SCIENCES, INC. CIN: 2019410 , United States, Active		$500M - $1B (As on Dec 31, 2025)	-	-
CARIS SCIENCE INC. CIN: 453632909 , United States, Active	Dec 26, 999	-	1760 (As on Dec 31, 2024)	-
MIRACA LIFE SCIENCES, INC. CIN: 621637129 , United States, Active	Dec 31, 1999	-	504 (As on Dec 31, 2022)	-

Caris Life Sciences got listed on Jun 18, 2025.

Click here to take a look at Caris Life Sciences's IPO in detail

Caris Life Sciences has raised a total funding of $1.23B over 9 rounds. Its first funding round was on Jan 09, 2017. Its latest funding round was a Series D round on Apr 07, 2025 for $168M. 6 investors participated in its latest round. Caris Life Sciences has 21 institutional investors.

Here is the list of recent funding rounds of Caris Life Sciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 07, 2025	$168M	Series D	-	-	Braidwell	Perceptive Advisors, Woodline Partners, Ghisallo Capital Management, Millennium Management, First Light Asset Management
Jan 19, 2023	Undisclosed	Conventional Debt	-	-	-	Orbimed, Braidwell
May 11, 2021	$830M	Series D	$7.83B	-	Sixth Street	T. Rowe Price, Silver Lake, Fidelity Investments, Coatue, Millennium Management, Neuberger Berman, Highland Capital Management, Columbia Threadneedle Investments, CPP Investments, Orbimed

Access funding benchmarks and valuations. Sign up today!

View details of Caris Life Sciences's funding rounds and investors

The founders of Caris Life Sciences is David Dean Halbert.

Here are the details of Caris Life Sciences' key team members:

David Dean Halbert: Founder of Caris Life Sciences.

View details of Caris Life Sciences's Founder profiles and Board Members

Caris Life Sciences' employee count trend

Caris Life Sciences has 61 employees as of Sep 26. Here is Caris Life Sciences's employee count trend over the years:

Employee count trend for Caris Life Sciences

Uncover Caris Life Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Caris Life Sciences include Guardant Health, Natera and BillionToOne. Here is the list of Top 10 competitors of Caris Life Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	80/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	79/100
3rd	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	71/100
4th	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
5th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	69/100
6th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
7th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Silver Lake, T. Rowe Price & 19 others	67/100
8th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	66/100
9th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	66/100
10th	NeoGenomics 2002, Fort Myers (United States), Public	Provider of cancer genetic diagnostic services	-	Ranger Investments, Aspen Capital & 1 others	65/100